Aurinia Pharmaceuticals Inc.'s SEC filings document the formal reporting record for a Canada-incorporated biopharmaceutical company commercializing LUPKYNIS and developing autoimmune-disease therapies. 8-K filings furnish operating and financial results, product revenue, license, collaboration and royalty revenue, research and development spending, guidance-related exhibits and other material-event disclosures.
The filings also cover proxy governance, executive appointments and compensatory arrangements, shareholder voting matters, capital-structure disclosures, share repurchase activity and material agreements. Recent transaction records include completed acquisition activity, tender-offer and merger mechanics, and contingent value right terms.
Aurinia Pharmaceuticals reports strong 2025 growth built around its lupus nephritis drug LUPKYNIS and a solid cash position. Net product sales reached $271.3 million, up 25% from 2024, driven by U.S. specialty pharmacy distribution and supply to its partner Otsuka for Europe and Japan.
Cash flows from operating activities rose to $135.7 million, a 206% increase, supporting a year-end cash, cash equivalents, restricted cash and investment balance of $398.0 million. Aurinia repurchased 12.2 million common shares for $98.2 million, reflecting active capital return alongside continued investment in its pipeline.
The company highlights LUPKYNIS’ clinical profile, updated treatment guidelines that favor early aggressive therapy, extensive patent and exclusivity protections, and an expanding autoimmune pipeline led by aritinercept, while acknowledging competitive, patent-challenge and reimbursement risks.
Aurinia Pharmaceuticals reported strong growth for 2025, driven by its lupus nephritis drug LUPKYNIS. Total revenue reached $283.1 million for the year, up 20% from 2024, with LUPKYNIS net product sales rising 25% to $271.3 million.
The company moved to solid profitability, with 2025 net income of $287.2 million versus $5.8 million a year earlier, helped by a large income tax benefit from releasing a valuation allowance on deferred tax assets. Cash, cash equivalents, restricted cash and investments were $398.0 million as of December 31, 2025, after repurchasing 12.2 million common shares for $98.2 million. For 2026, Aurinia guides to total revenue of $315–$325 million and LUPKYNIS net product sales of $305–$315 million, implying low- to mid-teens percentage growth.
Aurinia Pharmaceuticals Inc. insider activity: Chief Operating Officer Matthew Maxwell Donley reported a tax-related share disposition tied to equity compensation. On this Form 4, 32,901 shares of common stock were withheld at $14.4000 per share to satisfy tax obligations upon the vesting of restricted stock units. This was an automatic tax-withholding disposition, not an open-market trade, and Donley continued to hold 662,900 common shares directly after the transaction.
Aurinia Pharmaceuticals Inc. Chief Executive Officer Peter Greenleaf reported a Form 4 transaction involving company common stock. On February 20, 2026, 100,171 shares were disposed of at $14.40 per share in a tax-withholding disposition, meaning shares were withheld to cover tax obligations upon vesting of restricted stock units rather than sold in an open-market trade. After this transaction, Greenleaf directly owned 1,744,866 common shares.
Aurinia Pharmaceuticals Inc. Chief Financial Officer Joseph M. Miller reported a tax-related share disposition. On the vesting of restricted stock units, 32,424 shares of common stock were withheld at $14.40 per share to cover tax obligations, according to the footnote. After this withholding transaction, Miller directly owned 556,703 common shares.
Aurinia Pharmaceuticals Inc.'s EVP and General Counsel, Stephen P. Robertson, reported a Form 4 transaction involving company common stock. On February 20, 2026, 34,638 shares of common stock at $14.40 per share were disposed of to satisfy tax withholding obligations tied to vesting restricted stock units, rather than through an open-market sale. After this tax-withholding disposition, Robertson’s directly held ownership stood at 483,296 common shares.
Aurinia Pharmaceuticals senior vice president and chief medical officer Greg Keenan reported a routine share withholding tied to equity compensation. On 02/02/2026, 11,552 shares of common stock were withheld at $14.53 per share to satisfy tax obligations when restricted stock units vested.
After this tax-related withholding, Keenan beneficially owns 121,932 shares of Aurinia common stock, held directly. The filing reflects an administrative adjustment rather than an open-market purchase or sale, and confirms his ongoing equity stake in the company.
Aurinia Pharmaceuticals Inc. (AUPH) filed a Form 4 reporting a tax-related share withholding by a director. On 11/21/2025, a director had 2,716 common shares withheld at a price of $15.68 per share to cover tax obligations when restricted stock units vested. This was recorded as a disposition of shares for tax purposes, not an open-market sale. After this transaction, the director beneficially owns 22,775 common shares, held directly.
The filing clarifies that the reported transaction represents shares withheld to satisfy tax withholding obligations upon RSU vesting, which is a common administrative equity compensation event for insiders.
Aurinia Pharmaceuticals Inc. (AUPH) reported an insider equity transaction on a Form 4 involving one director. On 11/21/2025, the director had 6,039 common shares withheld at a price of $15.68 per share to cover tax withholding obligations tied to the vesting of restricted stock units. After this tax-related withholding, the director directly beneficially owned 14,592 common shares of Aurinia. This event reflects routine equity compensation and tax management rather than an open-market purchase or sale.
Aurinia Pharmaceuticals Inc. (AUPH) furnished an 8‑K on November 4, 2025 announcing it issued a press release for its financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1, with a Third Quarter 2025 Update as Exhibit 99.2.
The information was furnished under Item 2.02 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as specifically stated. The report was signed by Chief Financial Officer Joseph Miller.